Royalty Report: Drugs, Therapeutic, Proteins – Collection: 168576

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Proteins
  • ribonucleic acid
  • Arthritis
  • DNA

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 168576

License Grant
The Japanese Licensor hereby grants to Licensee an exclusive and non-transferable license, with the right to sublicense, to manufacture and sell the License Product in the Territory under the License Patent. Licensee shall notify Licensor in writing of the name of the sublicensee and the type and territorial scope of such sublicense within two (2) weeks after execution of such sublicense agreement.
License Property
License Product shall mean DT/IL-2 fusion protein which is produced by the fused genes which are comprised of a gene encoding IL-2 or its partial fragments and a gene encoding diphtheria toxin or its partial fragments, to be used as a pharmaceutical for human use and which is covered by the Licensed Patent.

License Product shall mean DT/IL-2 fusion protein which is produced by the fused genes which are comprised of a gene encoding IL-2 or its partial fragments and a gene encoding diphtheria toxin or its partial fragments, to be used as a pharmaceutical for human use and which is covered by the Licensed Patent.

Field of Use
This agreement pertains to the pharmaceutical industry.

IPSCIO Record ID: 237243

License Grant
Licensor grants to the United Kingdom Licensee a non-exclusive license, without the right to sublicense, in the territory in the field of use and under the Patent Rights to research, develop, make, have made, use, sell, have sold, offer for sale, have offered for sale, import, and export Licensed Products, and research, develop, use, and practice Licensed Processes only for the purposes of manufacturing or having manufactured the Licensed Products.

Licensor grants a non-exclusive license, without the right to sublicense, in the Territory to conduct preclinical research and/or pre-Phase II clinical trials ( or the equivalent of pre-Phase II clinical trials in the U.S. or other countries) involving the use of Licensed Products in indications outside of the Field of Use.

License Property
The Licensed Product means the first three (3) short consensus repeat protein domains of human complement receptor type 1 (CRI), derivatized to include a myristoyl peptide, having Licensees designation -070 or any successor product of such -070 which is an optimization or derivative of -070, the development, manufacture, use, sale, offer for sale, importation or distribution.
Field of Use
The field of use means the treatment of rheumatoid arthritis.

IPSCIO Record ID: 173859

License Grant
College hereby grants to Licensee and Licensee accepts, subject to the terms and conditions hereof, a worldwide exclusive commercial license, under Patent Rights to make and have made, to use and have used, to sell and have sold the Licensed Products, and to practice the Licensed Processes, for the life of Patent Rights.  Licensee agrees that during the period of exclusivity of this license in the United States that any products produced through the use of the Licensed Processes for sale in the United States will be manufactured substantially in the United States unless a waiver is obtained from the Federal government as provided in the regulations implementing Public Law 96-517.
License Property
Colleges U.S. Patent Application No. 377,386, filed May 13, 1982, entitled 'Hybrid Proteins' (now U.S. Patent No. 4,675,382).
Field of Use
This agreement pertains to the drug industry relating in the treatment of medical disorders.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.